Загрузка...
LRRK2 G2019S Mutations are associated with an increased cancer risk in Parkinson Disease
Leucine rich repeat kinase (LRRK2) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may non-specifically inhibi...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2978749/ https://ncbi.nlm.nih.gov/pubmed/20818610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mds.23314 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|